--- title: "Scholar Rock Readies for Apitegromab Launch Amid Risks" type: "News" locale: "en" url: "https://longbridge.com/en/news/295726510.md" description: "Scholar Rock (SRRK) held its Q2 earnings call, highlighting regulatory progress for apitegromab with an FDA BLA acceptance and a PDUFA date of Sept 30, 2026. The company emphasized dual manufacturing pathways to mitigate risks, strong cash reserves of $492 million, and commercial readiness. While management expressed optimism regarding clinical data and market potential, they acknowledged execution risks related to FDA inspections at Catalent's facility and third-party manufacturing dependencies." datetime: "2026-08-13T00:29:17.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295726510.md) - [en](https://longbridge.com/en/news/295726510.md) - [zh-HK](https://longbridge.com/zh-HK/news/295726510.md) --- # Scholar Rock Readies for Apitegromab Launch Amid Risks Scholar Rock Holding ((SRRK)) has held its Q2 earnings call. Read on for the main highlights of the call. ### Claim 55% Off TipRanks - Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions - Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks Scholar Rock’s latest earnings call struck an overall optimistic tone, emphasizing regulatory progress, clinical validation, and commercial readiness around its lead SMA drug apitegromab. Management acknowledged manufacturing and reimbursement risks, but framed them as manageable execution challenges against a backdrop of solid cash resources and clear unmet medical need in the SMA market. ## Regulatory Milestone: BLA Accepted with Firm PDUFA Date Apitegromab’s biologics license application was accepted by the FDA in April, locking in a September 30, 2026 PDUFA date and giving investors a clear near‑term catalyst. Management said the review is progressing well, positioning the company for a potential first approval in late 2026 if remaining manufacturing questions are resolved. ## Dual Manufacturing Paths Aim to De‑Risk U.S. Approval Scholar Rock highlighted two independent fill‑finish pathways, with Catalent Indiana and a second unnamed facility both supporting the BLA. The second site has already submitted its agreed data package, is under FDA review, and currently holds more launch‑ready vials than Catalent, providing redundancy if one site faces regulatory delays. ## European Strategy Built Around EMA Review and Germany Launch In Europe, apitegromab’s marketing application is under EMA review and presently references Catalent Indiana as the sole fill‑finish site. The company is in active dialogue with regulators to add the second facility and plans an initial commercial rollout in Germany, supported by a 50‑country platform targeting roughly 35,000 SMA patients previously treated with SMN‑targeted drugs. ## Pipeline Momentum Across Multiple Muscle‑Targeted Programs Management underscored broad clinical momentum beyond the lead SMA indication, citing strong enrollment in the Phase II OPAL study in infants and toddlers with SMA. The randomized Phase II FORGE trial in FSHD is now underway with a planned 60‑patient sample, while Phase I dosing of SRK‑439 continues, with top‑line safety and PK data expected later this year alongside favorable subcutaneous apitegromab PK/PD data reported earlier. ## Pivotal SAPPHIRE Data Underscore Efficacy Signal The SAPPHIRE pivotal trial delivered a statistically significant improvement on the Hammersmith Motor Function Scale, with a p‑value of 0.019 when apitegromab was added to ongoing SMN‑targeted therapy. This result is central to the approval case, suggesting that targeting muscle directly can provide meaningful functional gains on top of existing standard‑of‑care genetic treatments. ## Commercial Infrastructure Built and ‘Launch‑Ready’ Scholar Rock reported that its U.S. commercial organization is effectively ready to launch, with field teams positioned to cover about 140 SMA treatment centers and roughly 2,600 prescribing physicians. A dedicated patient services hub, Scholar Rock Supports, is prepared to help families navigate insurance approvals, scheduling, and logistical hurdles once apitegromab is available. ## Balance Sheet Strength and Flexible Financing Levers The company ended the quarter with $492 million in cash, cash equivalents, and marketable securities, including $63 million in net proceeds from an at‑the‑market equity program. Management also pointed to an additional $150 million that can be drawn from an existing debt facility upon approval and plans to monetize a priority review voucher, giving multiple levers to sustain operations through launch. ## Large Unmet Need Despite Widespread SMN Therapy Use Scholar Rock highlighted market research showing that about 78% of children and adults with SMA are already on SMN‑targeted therapies, yet an estimated 95% still suffer ongoing muscle atrophy. The company argues this gap creates a compelling opportunity for apitegromab as a first‑in‑class, muscle‑directed therapy designed to complement, rather than replace, existing genetic treatments. ## Regulatory Overhang from Catalent Inspection Classification The key remaining approvability concern stems from FDA observations at Catalent’s Indiana facility, which triggered the prior complete response letter and required a reinspection in April 2026. The final inspection classification remains pending, and both the FDA and EMA are closely monitoring the outcome, leaving some timing uncertainty around potential approval decisions. ## European Timeline Tied to U.S. Manufacturing Decision Because the current European application lists only Catalent Indiana, the EMA is waiting on the FDA’s classification of that site before moving toward a committee opinion. Scholar Rock hopes that adding the second fill‑finish facility into the MAA could reduce dependence on a single inspection outcome and improve visibility on the European approval path. ## Execution Risk from Third‑Party Manufacturing and Review Timelines While management emphasized that two independent fill‑finish paths limit single‑site risk, reliance on external CDMOs and regulators introduces unavoidable execution risk. Notably, the FDA’s classification timeline has already run longer than the typical 90‑day target, reminding investors that even well‑prepared programs can be slowed by factors outside the company’s direct control. ## Lack of Current Revenue Keeps Launch Timing in Focus Apitegromab remains an investigational product with no commercial revenue to date, leaving Scholar Rock entirely dependent on its cash reserves and financing tools. Future revenue timing will hinge on the FDA and EMA decisions, as well as how quickly manufacturing classifications and any MAA amendments are resolved. ## Payer Friction and Early Access Delays Anticipated The company warned that prior authorization is likely to be standard for apitegromab, mirroring other high‑cost SMA therapies and creating potential early access friction. Management expects a meaningful rate of initial insurer denials and appeals, estimating that average time from prescription to first infusion could exceed 60 days in the first six months after launch. ## Elevated Operating Spend as Commercial Build‑Out Continues Quarterly operating expenses reached $108.9 million, including $19.7 million of noncash stock‑based compensation, with SBC representing roughly 18.1% of the total. Scholar Rock has stepped up commercial investments while keeping overall spend broadly in line with the prior year, but the larger cost base will put pressure on cash burn as it transitions toward commercialization. ## Guidance and Outlook Emphasize Near‑Term Catalysts Looking ahead, management reiterated that the apitegromab BLA is under active FDA review with a September 30, 2026 PDUFA date and two independent manufacturing routes, including vials already staged at a third‑party packager. The company plans a staggered U.S. and German launch, expects payer‑driven delays early on, continues to advance OPAL, FORGE, and SRK‑439, and believes its sizable cash position plus potential debt and voucher proceeds can bridge the gap to a full commercial rollout. Scholar Rock’s earnings call painted a picture of a late‑stage biotech at an inflection point, supported by positive pivotal data, solid funding, and a largely built commercial machine. Investors will be watching closely as regulatory decisions on apitegromab and manufacturing sites unfold, with execution on approvals, payer access, and launch pacing set to determine whether the company can convert its clinical promise into durable revenue growth. ### Related Stocks - [SRRK.US](https://longbridge.com/en/quote/SRRK.US.md) ## Related News & Research - [Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab](https://longbridge.com/en/news/296153267.md) - [Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule](https://longbridge.com/en/news/295429730.md) - [Mid America Apartment Communities (MAA) And The Sun Belt Case For A Cheap Valuation](https://longbridge.com/en/news/296006880.md) - [West Family Investments Inc. Buys Shares of 7,697 Mid-America Apartment Communities, Inc. $MAA](https://longbridge.com/en/news/296470077.md) - [CAPR Stock News: Capricor Therapeutics Sued for Securities Fraud over Alleged Misrepresentations and Corresponding 64% Stock Drop](https://longbridge.com/en/news/296212809.md)